secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0001193125-23-111832
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports 100% complete remission in INB-100 Phase 1 leukemia trial; RP2D selected
--------------------------------------------------------------------------------

- 100% of evaluable patients (n=7) in durable CR; one patient progression-free beyond 3 years.
- Gamma-delta T cells expanded 82.9x at Dose Level 2 vs. standard haploidentical HSCT at 60 days.
- Dose Level 2 selected as recommended Phase 2 dose based on safety, tolerability, and expansion data.
- No dose-limiting toxicities observed; all GvHD low-grade and steroid-responsive.
- Conference call today at 10 a.m. ET; updated data expected at future medical meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523111832/0001193125-23-111832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523111832/d421859d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-111832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer